Company CVAbout Alivus Life Sciences Ltd 
Alivus Life Sciences Ltd
Mid Cap
Pharmaceuticals & Drugs
Glenmark Life Sciences Limited was incorporated as `Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited' dated 10 August 2018.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 24.51 Cr
Number of Shares
12.25 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
03-Aug-2021
12.25
24.51
14722222
2
Public Issue
06-Apr-2021
10.78
21.56
98004500
2
Bonus Issue
26-Mar-2021
98
1.96
7840360
2
Stock Split
09-Jul-2018
19.6
1.96
1500000
2
Preferential basis
29-Jun-2018
4.6
0.46
450090
2
Loan Conversion
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 11 Schemes (3.23%)
FIIs
Held by 66 FIIs (6.74%)
Promoter with highest holding
Nirma Limited (75.0%)
Highest Public shareholder
Polar Capital Funds Plc - Healthcare Opportunities (2.79%)
Individual Investors Holdings
10.99%
Board of Directors
Management
Designation
Remuneration
Glenn Saldanha
Chairman & Non Executive Dir.
0
V S Mani
Non Executive Director
0
Yasir Yusufali Rawjee
Managing Director & CEO
5.5 cr
Vinod Naik
E D & Wholetime Director
1.29 cr
Sridhar Gorthi
Independent Non Exe. Director
18.0 lacs
Manju Agarwal
Independent Non Exe. Director
12.0 lacs
Taruvai Laxminarayanan Easwar
Independent Non Exe. Director
10.0 lacs
Gita Nayyar
Independent Non Exe. Director
12.0 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
642 Cr
(Quarterly Results - Dec 2024)
Net Profit:
137 Cr
Pharmaceuticals & Drugs
INR 11,621 Cr (Mid Cap)
26.00
33
0.00%
-0.17
17.40%
4.55
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
